Working... Menu

A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01808040
Recruitment Status : Completed
First Posted : March 8, 2013
Last Update Posted : September 21, 2017
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:

In this study the investigators want to find out about the effects of this drug in women with metastatic breast cancer. The study has two major parts; dose escalation and dose expansion. In the first part or dose escalation, subjects will be treated at the lowest dose effective in men: 300 mg two times daily. Orteronel (TAK-700) will be increased to reach the highest dose tolerated in men: 400 mg two times daily. This part of the study is designed to see if female subjects can safely tolerate orteronel (TAK-700), and to measure the changes in estrogens and androgens at different levels of TAK-700.

In the second part of the study (dose expansion), seven women will be treated with the dose identified in the first part of the study as being safest and most effective. In this part of the study, the investigators want to see if orteronel (TAK-700) will routinely and significantly decrease the estrogen levels at the dose which will be used for any future studies.

Condition or disease Intervention/treatment Phase
Post Menopausal, Hormone Receptor Positive Breast Cancer Drug: TAK700 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer
Study Start Date : November 2012
Actual Primary Completion Date : July 2014
Actual Study Completion Date : December 9, 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1

Tak700 (orteronel) dose escalation schedule:

  • 1a 200 mg PO BID TAK700
  • 1b 200mg PO BID TAK + glucocorticoid

    1a 300mg PO BID TAK700 starting dose

    1b 300 mg po BID + glucocorticoid 2a 400mg PO BID TAK700 2b 400 mg po BID + glucocorticoid

Drug: TAK700
dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
Other Name: Orteronel

Primary Outcome Measures :
  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability as a way to determine the recommended phase 2 dose. [ Time Frame: one year ]
    Determine the RP2D of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer.

  2. decrease in serum estradiol level [ Time Frame: one year ]
    To demonstrate clinically significant decrease in serum estradiol following treatment with orteronel at RP2D in postmenopausal women with HR+ metastatic breast cancer.

Secondary Outcome Measures :
  1. Overall Response Rate [ Time Frame: one year ]
    Determine the overall response rate (ORR) and disease control rate (DCR) for orteronel in all patients treated with orteronel on protocol

  2. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: one year ]
    Determine toxicity of orteronel in patients being treated at the RP2D

  3. pharmacodynamic activity of orteronel with steroid and endocrine levels [ Time Frame: two years ]
    Demonstrate the pharmacodynamic activity of orteronel by assessing steroid hormone and other endocrine levels before and following administration of orteronel.

  4. response rate, progression-free survival and time to progression [ Time Frame: 2 years ]
    To determine the ORR, DCR, progression-free survival (PFS) and time-to-progression (TTP) in HR+ metastatic breast cancer patients receiving orteronel in the dose-expansion cohort

Other Outcome Measures:
  1. assess changes in serum estrogen, progesterone, androgen and other hormones [ Time Frame: 2 years ]
    Assess changes in serum estrogen, progesterone, androgen and other hormones in response to orteronel, and correlate tumor response to orteronel with reduction in serum levels of estrogens and androgens. See Table 4-1 and 4-2 for planned steroid hormone and other endocrine levels.

  2. Response to orteronel with AR and ER alpha expression [ Time Frame: 2 years ]
    Correlate response to orteronel with tumor expression of androgen receptor (AR), estrogen receptor alpha (ERα), and progesterone receptor (PgR), determined by immunohistochemistry (IHC) in primary and/or metastatic biopsies.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Voluntary written informed consent
  • Patients 18 years or older
  • Screening clinical laboratory values as specified below:
  • Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be the upper limit of normal (ULN).
  • Total bilirubin ≤ 1.5 x ULN.
  • Serum creatinine ≤ 1.5 × ULN or Estimated creatinine clearance using the Cockcroft-Gault formula must be greater than 50 mL/minute
  • Absolute neutrophil count (ANC) greater than 1000/L and platelet count greater than 75,000/L.
  • Serum potassium levels must be within institutional normal limits.
  • Serum magnesium and phosphorous levels must be ≥ the institutional lower limit of normal.
  • Screening calculated ejection fraction greater than or equal to the institutional upper limit of normal
  • Patients must have histologically confirmed breast cancer that is Metastatic OR Incurable and locally advanced
  • Patients must have histologically confirmed HR+ breast cancer.
  • Patients must have measureable or evaluable disease
  • ECOG performance status <2 (Karnofsky >60%)
  • Patients must be postmenopausal women.

Inclusion Criteria for Dose Expansion Cohort:

  • All of the criteria listed in above in addition to those below:
  • Patients must have measurable disease.
  • Patients may not have received more than 1 prior line of endocrine therapy in the metastatic setting.
  • Patients may not have received any cytotoxic chemotherapy for treatment in the metastatic setting.

Exclusion Criteria:

  • Exclusion Criteria for Dose Escalation Cohort
  • Patients meeting any of the following exclusion criteria are not to be enrolled in the study.
  • Patients who have not discontinued all prior medical therapy for breast cancer (with the exception of bisphosphonates or denosumab) at least 28 days prior to first dose of orteronel.
  • Patients who are taking any form of other exogenous hormonal therapy within 28 days prior to first dose of orteronel.
  • Patients should not have received radiotherapy within 14 days prior to the first dose of orteronel.
  • Patients should have recovered to baseline or < grade 1 for all-prior treatment related toxicities.
  • EKG abnormalities of:

    • Q-wave infarction, unless identified 6 or more months prior to screening QTc interval > 470 msec, the upper limit of normal for women.
    • Known hypersensitivity to compounds related to orteronel or to orteronel excipients.
    • Uncontrolled hypertension despite appropriate medical therapy
    • Known active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with participation in this study.
  • Likely inability to comply with the protocol or cooperate fully with the investigator and site personnel.
  • Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of orteronel, including difficulty or inability to swallow tablets.
  • Patients with known endocrine disorders including, but not limited to, Cushing's, or Addison's disease.
  • Patients with known brain metastases are excluded unless they have had definitive treatment (e.g. whole brain radiotherapy or surgery or stereotactic radiation) for brain metastases with evidence of stable/improved disease on repeat imaging following definitive treatment.
  • Patients on medications with the potential for significant interaction with orteronel.
  • Patients with serious medical illness
  • Patients with an estimated life expectancy of less than 3 months as determined by the treating physician.
  • Prior therapy with abiraterone, or aminoglutethimide.

Exclusion Criteria for Dose Expansion Cohort Patients meeting any of the following exclusion criteria are not to be enrolled in the study:

  • They are ineligible by virtue of meeting any exclusion criteria above. Patients with known brain metastases will be excluded from this portion of the clinical trial (which will assess PFS and TTP) because of their relatively poor overall prognosis.
  • Patients with HER2+ breast cancer are also excluded from this portion of the study as HER2-targeted therapy would generally be considered appropriate for the HER2+ patient population meeting the entry criteria for the dose expansion cohort.
  • They have received treatment with orteronel or another lyase inhibitor in the past.
  • Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of in situ malignancies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01808040

Layout table for location information
United States, Wisconsin
University of Wisconsin
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
University of Wisconsin, Madison
Millennium Pharmaceuticals, Inc.
Layout table for investigator information
Principal Investigator: Amye J Tevaarwerk, MD University of Wisconsin, Madison

Layout table for additonal information
Responsible Party: University of Wisconsin, Madison Identifier: NCT01808040     History of Changes
Other Study ID Numbers: CO11109
First Posted: March 8, 2013    Key Record Dates
Last Update Posted: September 21, 2017
Last Verified: September 2017

Keywords provided by University of Wisconsin, Madison:
breast cancer
ER positive
PR positive
post menopausal

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs